Radiotherapy (RT) 
Transmural invasion is also common. Since the proximity of critical normal structures limits the extent of dissection, locoregional failure, as one might expect, is a common problem following radical sur- IFive-year actuarial rate.
gery, although it may take prolonged follow-up to see it enierge (Table 5 ) 7, 8, 11, 13, [20] [21] [22] Unfortunately, very few series have examined the correlates of such recurrence. In a recent study performed in Liverpool, England,22 the risk of locoregional recurrence was much greater when the circumferential margin was involved by tumor (failure rate, 11/22, or 50%) than when it was not (4/30, or 13%). These authors, however, gave no information on the possible correlates of margin involvement, especially ones that could be assessed preoperatively (eg, tumor size or computed tomography [CT] findings).
Not all the randomized trials listed in Table 1 have reported locoregional failure rates. Either preoperative or postoperative RT reduced the risk of locoregional failure substantially in those series with 3 years or more of follow-up (Table 5 ). Of note, this effect has not been seen in those series with shorter follow-up.
IMPACT OF ADJUVANT RT ON SURVIVAL
As noted, nearly all randomized studies of preoperative RT have been flawed by use of inadequate RT doses (Table 1) . Perhaps in part because of this, the results of these trials have been disappointing, showing little if any improvement in overall survival rates.
Two randomized studies of postoperative RT reported no improvement in survival in the experimental arms, although the short duration of follow-up in one of these studies rendered this finding inconclusive (Table 1) . Postoperative RT also has been used in nonrandomized studies in relatively small groups of patients. [23] [24] [25] [26] In one retrospective series,25 patients with pathologically normal regional lymph nodes appeared to benefit from such treatment, but there was no survival advantage for patients with lymph node involvement. To our knowledge, the optimal timing of RT and CTh in relation to one another has not been explored in randomized studies. An approach other than concurrent administration is to give these modalities sequentially, which may reduce toxic reactions considerably but also may lessen the antitumor effect. A recent trial in Scandinavia found sequential CTh (cisplatin and bleomycin) and radiation produced results similar to those obtained by using preoperative RT alone.'2 Further studies of this approach are in progress. The European Organization for Research and Treatment of Cancer (protocol 40881) is comparing surgery alone with preoperative RT (37 Gy, delivered in ten fractions on days 1 to 5 and days 22 to 26) and cisplatin (100 mg/m2 given within 3 days prior to RT) in patients with stage I or II squamous cell carcinoma of the thoracic esophagus; surgery is to be performed 2 to 4 weeks later.
Exploration of the best timing of chemoradiotherapy in relation to surgery has been limited. Postoperative concurrent chemoradiotherapy has also been given with only limited severe acute toxic reactions. 48 Another approach is to give either CTh or RT alone prior to surgery and to use the other modality following surgery. 14'210 At present, there is no consensus on which sequencing or timing approach achieves the best results.
Certainly, no one has yet developed an optimal regimen for controlling either local or distant disease. For example, in a study performed at the University of Michigan,40 95% (41/43) of patients completed a 21-day course of concurrent cisplatin, 5-FU, vinblastine, and RT (37.50 Gy in 15 daily fractions or 45 Gy in 30 fractions delivered twice daily) and then underwent exploratory surgery. Complete resection of tumor was achieved in 84% of patients. In a recent update,49 the 5-year survival rate for the entire entering group of 43 patients was 34%. Of note, this rate was 60% among patients who had a pathologic CR vs 32% for those having residual tumor present following resection. Of the 36 patients whose tumors were resected, none had local failure as the first site of recurrence. There was a 3% incidence of regional failure (within the irradiated mediastinum), a 47% incidence of distant failure only, and a 14% incidence of both regional and distant failure. In a Duke University study of 58 patients undergoing complete gross tumor resection following RT and CTh with cisplatin or carboplatin and either 5-FU (for squamous carcinomas) or etoposide (for adenocarcinomas), 14% had failures initially in local sites, 29% at distant sites only, and 10% at both local and distant sites.41 In a recent update,50 the 5-year actuarial locoregional failure rate had reached about 48% and the overall survival rate was only 14%.
TOXICITY OF COMBINED-MODALITY REGIMENS
Toxicity from these regimens also remains a problem. Nearly all patients suffer varying degrees of anorexia and fatigue that eventually resolve, although sometimes not for months following the completion of therapy. In the University of Michigan experience,40 86% of patients had transient esophagitis and secondary dysphagia, and 79% required nutritional support. Grade 3 or 4 leukopenia was encountered in 93% of patients, with grade 3 or 4 thrombocytopenia seen in 23% and 33% requiring RBC transfusions. Two preoperative deaths (5%) occurred due to granulocytopenia and sepsis. In the Duke University study,41 1% of evaluable patients (1/143) died of treatment-related bleeding during CTh, with a perioperative mortality rate (among patients undergoing surgery) of 17% (12/72).
In practical terms, it may be easier to deliver both RT and CTh preoperatively, because of the prolonged recovery period that often follows surgery. Preoperative combined-modality treatment does not appear to increase substantially the risk of postoperative complications in most retrospective series. However, two randomized studies have reported an increased risk of severe complications following surgery in patients treated with neoadjuvant chemoradiotherapy45 or preoperative CTh alone.33 Of note, the risk of perioperative mortality in the Duke University study was related both to patient age (4/5 patients older than 70 years died postoperatively vs 6/53 patients [11%] younger than 70 years) and preoperative RT dose (4/7 patients receiving more than 50 Gy died vs 6/51 patients [12%] receiving 50 Gy or less.50 When salvage esophagectomy was attempted in 11 patients who had received previously 60 Gy, the perioperative mortality rate was 36%.4 FUTURE DIRECTIONS A number of approaches to improving these results recently have been under investigation. Some of the recent and ongoing studies are reviewed below.
Some strategies have modified the RT regimens, CTh regimens, or both used in past studies. At Rush-Presbyterian-St. Luke's Medical Center in Chicago, accelerated RT (2 Gy given twice daily) has been used with concomitant 5-FU and cisplatin postoperatively in patients with resections.51 While local control has been excellent (14/15 patients), severe late complications were seen in 3 patients (ulcerations of pulled-up gastric mucosa in 2 patients and tracheoesophageal fistula in 1 patient), including 1 death. Further study of this approach, but with a reduced RT dose (1.7 Gy given twice daily), is ongoing.
A program at the University of Chicago is using two induction cycles of cisplatin, 5-FU, and leucovorin (PFL), followed by surgical resection in operable candidates; all patients then receive concurrent chemoradiotherapy using 5-FU, hydroxyurea (employed as a radiation-sensitizing drug), and radiation doses of 50 to 60 Gy. Tables 2 to 4 (ie, supraclavicular, celiac axis, and perigastric)? How far do the RT field borders need to extend above and below the grossly apparent primary tumor? There is no agreement on these points. Some of the excessive toxic reactions seen in the series discussed above may have been avoided had smaller RT fields or doses been used, but such reductions may also increase the risk of locoregional failures. These issues await exploration.
A very different but complementary approach would be to tailor the treatment to the tumor. That is, patients who have localized but unresectable disease might benefit from preoperative treatment, but some patients may have distant metastases that are discovered only at the time of surgery. Further, as discussed previously, some patients with very early disease are likely to be cured with surgery alone, and hence can be spared the potential side effects of preoperative CTh and RT. Should the surgical specimen show transmural invasion or abnormal regional nodes, then postoperative treatment could be given. By using such a strategy, only patients likely to derive a benefit will receive adjuvant therapy.
Imaging studies are widely used to evaluate resectability and metastatic spread preoperatively. Such tests, however, are often inaccurate when compared with surgical findings.56-60 For example, transesophageal ultrasound was only 70% accurate in determining whether periesophageal lymph nodes were involved by tumor in one recent study,6' and only 45% accurate in an older study.62 The accuracy of CT and conventional transabdominal ultrasound in predicting celiac axis adenopathy was only 30 and 48%, respectively, in a recent series.59 Their accuracy was better (80%) in assessing metastases to the liver or other intra-abdominal sites.
Disease extent in patients with pancreatic carcinoma can be assessed very accurately with laparoscopy.63 However, there has been only very limited experience with the use of minimally invasive surgery for the staging of esophageal carcinoma64 or other thoracic lesions. 65 We therefore recently began a collaborative protocol with the Joint Center for Radiation Therapy, the Brigham and Women's Hospital, and the Dana-Farber Cancer Institute to test the accuracy and clinical value of pretreatment surgical staging with thoracoscopy and laparoscopy in patients with apparently limited disease. The information obtained from this staging will be used to determine the overall treatment plan. Patients with distant metastases (eg, liver metastases, pleural or peritoneal seeding, para-aortic adenopathy) will be removed from study. Patients found to have extraesophageal tumor extension, mediastinal adenopathy, or celiac axis or perigastric adenopathy will receive concurrent chemoradiotherapy preoperatively. Patients with no evidence of extraesophageal spread or adenopathy will undergo surgical exploration; if transmural extension, abnormal mediastinal nodes, or perigastric and celiac axis nodes are found or if the resection margins are involved by tumor, then patients will receive the identical adjuvant combinedmodality therapy as those treated preoperatively. Patients with none of these conditions will be observed only. We will thus gather information on the accuracy of such surgical staging and correlate this with the results of noninvasive studies; compare, for the first time, the toxic reactions of identical preoperative and postoperative combined-modality therapy; and test whether such a strategy can limit the inappropriate use of chemoradiotherapy and exploratory surgery.
CONCLUSIONS
Randomized trials have shown that giving preoperative RT alone is safe but does not substantially increase resectability rates. Adequate doses of either preoperative or postoperative RT will significantly reduce the risk of locoregional failure; however, no improvement is seen in survival rates due to the substantial risk of distant failure associated with these tumors. Conversely, systemic therapy appears unlikely to be of much benefit unless the maximum possible rate of locoregional control is obtained. Hence, further investigation of the role of RT in patients with potentially resectable esophageal cancers will focus on combined-modality therapy. Although this approach remains promising, only randomized prospective studies will reveal whether patients truly benefit from such treatment. The optimal CTh and RT regimens and the optimal scheduling of these modalities with regards to each other and surgery are unknown at present. Accurate surgical staging may improve our ability to select the most efficacious and least toxic treatment approach for each patient.
